Information intended for UK healthcare professionals only. 

image001

This formulary decision guide was developed from content provided by LogixX Pharma Limited in a format developed by Guidelines in PracticeRenascience Pharma Limited carried out full medical approval to ensure compliance with regulations.

Renascience Image File_PNG_NEW

View Otigo® (phenazone/lidocaine hydrochloride) prescribing information and adverse event reporting information here

Otigo FDG V7_Final

Key points

Otigo®:

  • is recommended by NICE guidance (NG91) as first line choice of treatment for Acute Otitis Media (AOM)1
  • is the UK’s only licensed ear drop for AOM pain relief as recommeded by NICE1
  • provides ear pain relief within five minutes2
  • contains phenazone­3 —a long acting non-steroidal anti-inflammatory, analgesic and antipyretic
  • contains lidocaine3 —a fast acting anaesthetic
  • has no age restrictions, no dose adjustments or interaction concerns.2

View the PDF of the formulary decision guide here 

Drug name

Otigo® phenazone 40 mg/g lidocaine hydrochloride 10 mg/g ear drops, solution

Indication3

Otigo® is intended for local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation:

  • acute, congestive otitis media
  • otitis in influenza, the so called viral bullous otitis
  • barotraumatic otitis.

Prevalence

  • It is estimated that more than 80% of children will suffer with AOM before their third birthday4
  • AOM is the sixth most common infectious reason for children to attend in-hours primary care, with over 500,000 consultations per annum, at an estimated NHS cost of £13.5 million5
  • AOM is the most common reason for children to be prescribed antibiotics and accounts for 14% of antibiotic prescribing in under 3 year olds6,7
  • Around 60% of under 4 year olds have at least one episode of AOM and 40% will have six or more recurrences by the age of 7 years old.4,7

unnamed 2

Antimicrobial resistance (AMR)

NHS Frontline and AMR

  • AMR diseases are estimated to cause at least 700,000 deaths around the world each year8
  • The figure is predicted to rise to 10 million deaths, alongside a cumulative cost of $100 trillion, by 2050 if no action is taken8
  • A 20% change in prescribing antibiotics for AOM could have important effects on AMR9
  • Ear pain is the most prevalent, presenting symptom of AOM10
  • Otigo® as an anaesthetic, anti-inflammatory, and analgesic ear drop that could help contribute in reducing inappropriate antibiotic consumption.10

NICE guidance (NG91)1

Dosage and administration3

  • Otigo® acts locally therefore, dosage adjustments based on age are not necessary
  • Otigo® is suitable for use both in adults and children
  • The bottle comes with a dropper applicator
  • Instil four drops, two or three times daily, into the external auditory canal of the affected ear, slightly pressing the elastic part of the dropper.

unnamed

Contraindications3

This medicinal product should not be administered in the following cases:

  • hypersensitivity to the active substances or to any of the excipients sodium thiosulfate, ethanol, glycerol, and purified water
  • infectious or traumatic perforation of the tympanic membrane (including myringotomy).

References

  1. NICE. Otitis media (acute): antimicrobial prescribing. NICE Guideline 91. NICE, 2018 (last updated March 2022). Available at: www.nice.org.uk/ng91.
  2. LogixX Pharma. Otigo® for Acute Otitis Media presentation. OTI-UK-006-PR. 2022.
  3. Renascience Pharma Limited. Otigo 40 mg/10 mg/g ear drops, solution—summary of product characteristics. www.medicines.org.uk/emc/ (accessed 27 April 2022).
  4. Vergison A et al. Lancet Infect Dis. 2010; 10: 195–203.
  5. Study Protocol–Children’s drops for ear pain in acute otitis media: the CEDAR Randomised Controlled Trial (EudraCT number: 2014-004016-11).
  6. Williamson I et al. Br J Gen Pract 2006; 56: 170-175.
  7. Suzuki H et al. BMJ Open 2020; 10:e035343. doi:10.1136/bmjopen-2019-035343.
  8. Tackling Antimicrobial Resistance 2019–2024: The UK’s five-year national action plan. Jan 2019.
  9. Costelloe C et al. BMJ 2010; 340:c2096. doi. 10.1136/bmj.c2096.
  10. Venekamp P et al. Clinical Updates BMJ 2020; 371: m4238 doi.10.1136/bmj.m4238.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Renascience Pharma Medical Information: 01582 227 470 or email: medical@renasciencepharma.com  

 OTI-UK-027-HO

Date of preparation: June 2022